TransCode Therapeutics holds annual shareholder meeting

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc.

RNAZ

0.00
  • TransCode Therapeutics held its 2026 annual stockholder meeting on July 202, 2026.
  • Stockholders authorized issuance of common stock upon conversion of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock.
  • Stockholders authorized issuance of common stock upon conversion of Series C Non-Voting Convertible Preferred Stock.
  • Stockholders also authorized issuance of common stock under the Standby Equity Purchase Agreement with YA II PN, Ltd. and related convertible promissory notes.
  • The votes approved the issuances; the filing does not confirm any conversions or share issuances have occurred.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-085073), on July 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.